CD30 is a 120-kD transmembrane glycoprotein and a member of the tumor necrosis factor receptor superfamily member 8 (TNFRSF8). It interacts with TRAF2 or TRAF5 proteins mediating activation of Nuclear Factor kappa B (NF-κB). NF-κB affects multiple signal transduction pathways and plays a central role in cellular proliferation and differentiation. and is highly expressed in lymphoma with limited expression in healthy tissues, making it an ideal target for antibody-based therapies. Recently, in clinical trials for relapsed/refractory Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), brentuximab vedotin demonstrated high response rates as a single agent leading to its accelerated approval by the Food and Drug Administration (FDA) for treatment of these lymphomas under the brand name Adcetris?. Brentuximab vedotin is an antibody-drug conjugate, which couples an anti-CD30 antibody (SGN-30) to the synthetic anti-tubulin agent MMAE.
Alimchandani M, Wang Z-F, Miettinen M. CD30 EXPRESSION IN MALIGNANT VASCULAR TUMORS AND ITS DIAGNOSTIC AND CLINICAL IMPLICATIONS A: A STUDY OF 146 CASES. Applied immunohistochemistry & molecular morphology?: AIMM / official publication of the Society for Applied Immunohistochemistry. 2014;22(5):358-362.
Dabir S, Kresak A, Yang M, Fu P, Wildey G, Dowlati A. CD30 is a potential therapeutic target in malignant mesothelioma. Molecular cancer therapeutics. 2015;14(3):740-746. doi:10.1158/1535-7163.MCT-14-0972.
Muta H, Podack E R. CD30: from basic research to cancer therapy[J]. Immunologic research, 2013, 57(1-3): 151-158.